UROwebinar: Cracking the code of ARPI resistance in mCRPC - Molecular insights and biology driven treatment solutions

 Organised by the European School of Urology and the EAU Section of Oncological Urology, this UROwebinar will explore the evolving landscape of metastatic castration-resistant prostate cancer (mCRPC) management after androgen receptor pathway inhibitors (ARPIs).

 mCRPC remains a major therapeutic challenge, particularly after progression on ARPIs. Despite initial efficacy, resistance to ARPIs inevitably emerges through heterogeneous mechanisms, including androgen receptor amplification or mutation, splice variants (such as AR-V7), intratumoral androgen synthesis, activation of bypass signalling pathways, and lineage plasticity with neuroendocrine differentiation. Understanding these biological drivers of resistance is critical to guide subsequent treatment selection and sequencing.

 This webinar will discuss the molecular mechanisms of resistance integrated with current evidence and emerging strategies to optimise personalised care.

Acknowledgement: Medical writing support was provided by Accenture Song Life Sciences with unrestricted funding from our industry partner, with no involvement in the programme or speaker selection.